Effects of Fluticasone Furoate Nasal Spray on Parameters of Eosinophilic Inflammation in Patients With Nasal Polyposis and Perennial Allergic Rhinitis

Ann Otol Rhinol Laryngol. 2017 Aug;126(8):573-580. doi: 10.1177/0003489417713505. Epub 2017 Jun 6.

Abstract

Objectives: Regulated on activation normal T cell expressed and secreted (RANTES) and eotaxin-2 have been postulated to be responsible for eosinophilia in chronically inflamed nasal mucosa. This study evaluated mucosal production of RANTES and eotaxin-2 in patients with perennial allergic rhinitis (PAR) and nonallergic and allergic form of chronic rhinosinusitis with nasal polyps (CRSwNP) before and after nasal corticosteroid treatment.

Methods: Twenty patients with PAR, 20 nonallergic and 20 allergic CRSwNP patients, and 20 healthy controls were included. The RANTES and eotaxin-2 levels were measured in nasal secretion samples. The patients with chronic inflammation were treated with fluticasone furoate nasal spray for 2 weeks. Cytological examination and measurement of RANTES and eotaxin-2 in nasal fluid were performed before and after the treatment.

Results: The levels of RANTES were higher in patients with PAR ( P < .05) and nonallergic ( P < .01) and allergic CRSwNP patients ( P < .001) compared to controls. Eotaxin-2 levels were higher in all 3 inflammation groups compared to healthy subjects ( P < .001). After the treatment, we found a significant decrease of RANTES and eotaxin-2 concentrations ( P < .001) in all 3 groups of patients.

Conclusion: The levels of RANTES and eotaxin-2 in nasal fluid could be reliable markers for assessing corticosteroid administration outcomes.

Keywords: allergic rhinitis; chemokines; chronic rhinosinusitis; corticosteroids; inflammation; nasal polyps.

MeSH terms

  • Adult
  • Androstadienes / therapeutic use*
  • Case-Control Studies
  • Chemokine CCL24 / metabolism
  • Chemokine CCL5 / metabolism
  • Chronic Disease
  • Enzyme-Linked Immunosorbent Assay
  • Eosinophilia / drug therapy
  • Eosinophilia / metabolism
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Inflammation
  • Male
  • Middle Aged
  • Nasal Mucosa / metabolism
  • Nasal Polyps / drug therapy*
  • Nasal Polyps / metabolism
  • Nasal Sprays
  • Rhinitis / drug therapy*
  • Rhinitis / metabolism
  • Rhinitis, Allergic / drug therapy*
  • Rhinitis, Allergic / metabolism
  • Sinusitis / drug therapy*
  • Sinusitis / metabolism

Substances

  • Androstadienes
  • CCL24 protein, human
  • CCL5 protein, human
  • Chemokine CCL24
  • Chemokine CCL5
  • Glucocorticoids
  • Nasal Sprays
  • fluticasone furoate